Ⓐ
PeptiBrief
Endocrine

Growth hormone-releasing factor signalling

Growth hormone-releasing factor receptor activation stimulates pituitary growth hormone secretion.

Biological pathway

GHRH receptor activation increases cyclic AMP in pituitary somatotrophs and promotes growth hormone release with downstream IGF-1 signalling.

Evidence summary

Tesamorelin has strong human pharmacology and clinical evidence for activating this pathway in its licensed HIV-associated lipodystrophy context.

Limitations

Endocrine activity does not establish weight-loss benefit or support use outside studied indications.

Peptides linked to this mechanism

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.